Systemic lupus erythematosus (SLE, lupus) and systemic sclerosis (sderoderma) are prototypical systemic autoimmune diseases affecting multiple organ systems and characterized by the presence of autoantibodies. For the purpose of this article, the term lupus will be used to refer to the systemic form of the disease and the term discoid lupus will refer to the isolated skin disease. Similarly, the term scleroderma will be used to refer to systemic sclerosis, not to morphea or localized scleroderma that is confined to the skin. These diseases are considered autoimmune because a)tissue damage is mediated by immune cells and immune cell products; b) antibodies that recognize elements of host tissue are produced on a chronic basis; and c) there is no identified external stimulus against which an immune response can be considered appropriately directed. It has long been postulated that such an external stimulus exists and provides the trigger or initiating event. Persistence of disease, and perhaps its severity as well, is dependent on a complex interplay between host tissue and immune responses presumably based on genetic features. Additionally, both lupus and scleroderma have a female preponderance, with an overall female-to-male ratio of approximately 4:1 (1,2), suggesting that sex hormones or pregnancy-related events influence disease susceptibility.
Thus, both genetic factors and sex hormones are thought to play important roles in disease risk and these features account for the occasional familial clustering and the strong female preponderance. However, these two factors together make up only a small portion of the risk, suggesting that some environmental or acquired exposure(s) is necessary for disease expression.
Interest in the possibility that environmental exposures are important in the development of scleroderma comes from compelling evidence that several pseudo-sderodermatous conditions are triggered by the ingestion of, or exposure to, certain chemicals. For example, ingestion of contaminated rape seed oil resulted in the toxic oil syndrome in Spain in 1981 (3) , and a contaminated tryptophan/protein powder nutritional supplement was associated with the eosiniophilia myalgia syndrome in the United States in the late 1980s (4) . Additionally, vinyl chloride disease occurred in heavily exposed workers in that industry until the syndrome was recognized and changes made to reduce the level of exposure (5) . All these conditions, however, differ in many clinical features from idiopathic scieroderma, hence the term pseudoscleroderma or sderodermalike conditions, and provide limited insight into the pathogenesis of systemic sclerosis.
Similarly in the case of lupus, a syndrome of drug-induced lupus is well known and associated with several widely used medications. In the drug-induced form of the disease, signs and symptoms are similar to, if not identical with, the idiopathic disease, but the drug-induced form is usually milder and symptoms remit on drug cessation.
The 24 months had an adjusted RR of 5.3 (95% CI, 1.5-18.6), whereas the combination of estrogen plus progestogen had an insignificantly elevated RR of 2.0 (95% CI, 0.8-5.0). Participants in this study were almost exclusively white; these results should be applied with caution to a nonwhite population.
These studies found no significant association of smoking status, body mass index (6,7), hysterectomy, and oophorectomy (7) with the outcome of SLE or discoid lupus.
In terms of oral contraceptive (OC) use and the risk of developing SLE, SanchezGuerrero et al. (9) reported a study analogous to the hormone replacement study discussed above, using the Nurses' Health Study cohort. In summary, estrogen replacement therapy in postmenopausal women may increase the risk of developing lupus, scleroderma, and Raynaud disease, although the increase in risk is relatively modest. Evidence to date indicates that the addition of a progestogen to estrogen may serve to ameliorate this risk.
OCs may play a role in disease susceptibility in lupus, but evidence to date suggests this is not the case for sderoderma. It should be mentioned that these effects refer to the use of medications before disease onset and do not necessarily imply that the drugs would increase the severity ofestablished disease.
The discussion above has concentrated on the various medical uses for exogenous estrogens as they affect the risk of autoimmune disease. There are potential environmental endocrine modulators in the form of pesticides that could also influence the risk for these diseases. Certain pesticides are known to be endocrine disrupters including polychlorinated biphenyls (PCBs), DDT metabolites, and 2,3,7,8-tetrachlorodibenzo~p-dioxin (TCDD). PCBs exert antiestrogen activity by inhibiting estrogenmediated signal transduction (13, 14) . In an analogous fashion, the longlasting metabolite of DDT (p,p-DDE) can bind to the androgen receptor and disrupt hormonal signaling (13 Several epidemiologic studies have failed to find a significant association between silicone breast implants and the development of scleroderma (22, (24) (25) (26) (27) . One of these studies (22) also evaluated the risk of any implanted medical device, including pacemakers, joint prostheses, and indwelling catheters/shunts, many of which also include silicone products as part of the device. No association with scleroderma was found for these devices. Additional sources of silicone exposure through occupations and hobbies were examined by these investigators, but, again, no association was demonstrated. Silica and silicone exposure is discussed in greater detail in another artide in this monograph (28) .
Solvent Exposure
The role oforganic solvents and other chemicals has been suspected as contributing to disease risk in scleroderma on the basis of several case reports [(17,29-45) ; for review see Silman and Hochberg (46) (50, 51) and can reduce both the humoral and cell-mediated response (52) (53) (54) (57, 58 
